Weight loss and IUD for early-stage endometrial cancer
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a weight-loss medication (tirzepatide) combined with a hormonal intrauterine device (IUD) to treat early-stage endometrial cancer or precancerous changes. The goal is to see if this approach can make the condition go away and possibly avoid more invasive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of endometrial intraepithelial neoplasia (EIN) or early-stage (grade 1) endometrial cancer.
- Your body mass index (BMI) is 30 or higher, meaning you are considered obese.
- You have at least one obesity-related condition like high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea.
- If you have endometrial cancer, it must be stage 1A, meaning it has not spread deeply into the muscle of the uterus or elsewhere.
- If you have EIN, there is no spread outside the uterus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
This trial tests doing weight-loss surgery at the same time as laparoscopic uterus (womb) surgery for people with certain early uterine lining conditions. It may help lower risk from severe obesity while treating the uterine condition.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Hear when a new Endometrial Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.